DOCS
The honeymoon phase looks over
Truist Securities just took Doximity out behind the bleachers and handed it a Hold rating, down from Buy. It also sliced the price target to $29 from $37, basically saying: the company’s still standing, but the easy growth days are getting harder to find.
What changed?
The firm pointed to a few things that make investors sweat a little:
- less visibility into where pharmaceutical digital marketing budgets are headed
- pressure from what Truist called “mounting structural risks”
- expectations that fiscal 2027 growth could land below consensus
In plain English: Doximity is starting to look less like a turbocharged growth rocket and more like a platform that has to prove it can keep the engine humming once the hype cools off.
Why the Street is getting twitchy
Truist’s note comes as pharma buyers are reportedly scrutinizing every extra dollar they spend, which is not exactly the kind of backdrop growth investors write love letters about. The firm also thinks Doximity may be drifting from “growth leader” to a more mature platform, with possible market share erosion lurking in the background.
And this isn’t happening in a vacuum. The company recently announced its CFO resignation, which adds a little extra awkwardness right when the Street is already asking tougher questions.
The rest of Wall Street isn’t exactly shouting, either
Truist wasn’t alone in dialing back expectations. BofA cut its price target to $47 from $56 but kept a Buy, while Evercore ISI downgraded the stock to In Line from Outperform and trimmed its target to $25 from $30.
Big picture: Doximity isn’t getting destroyed here, but the market is clearly moving from “show me the growth” to “show me the next act.”